Drug Profile
Ciprofloxacin pulsatile - MiddleBrook
Alternative Names: Ciprofloxacin PULSYS™ - MiddleBrook; Pulsatile ciprofloxacin - MiddleBrookLatest Information Update: 04 Dec 2021
Price :
$50
*
At a glance
- Originator Advancis Pharmaceutical
- Developer MiddleBrook Pharmaceuticals
- Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Urinary tract infections
Most Recent Events
- 26 Aug 2009 No development reported - Preclinical for Bacterial infections in USA (PO)
- 26 Aug 2009 No development reported - Preclinical for Urinary tract infections in USA (PO)
- 29 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals